Eliem Therapeutics Statistics
Total Valuation
ELYM has a market cap or net worth of $228.44 million. The enterprise value is $123.64 million.
| Market Cap | 228.44M |
| Enterprise Value | 123.64M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, before market open.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ELYM has 27.72 million shares outstanding. The number of shares has increased by 4.33% in one year.
| Shares Outstanding | 27.72M |
| Shares Change (YoY) | +4.33% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 26.12% |
| Owned by Institutions (%) | 73.20% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.03, with a Debt / Equity ratio of 0.00.
| Current Ratio | 37.03 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.30% and return on invested capital (ROIC) is -18.61%.
| Return on Equity (ROE) | -13.30% |
| Return on Assets (ROA) | -12.90% |
| Return on Capital (ROIC) | -18.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +191.52% in the last 52 weeks. The beta is -0.35, so ELYM's price volatility has been lower than the market average.
| Beta (1Y) | -0.35 |
| 52-Week Price Change | +191.52% |
| 50-Day Moving Average | 4.74 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 61.35 |
| Average Volume (30 Days) | 879,893 |
Short Selling Information
The latest short interest is 56,729, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 56,729 |
| Short Previous Month | 601,081 |
| Short % of Shares Out | 0.20% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.84M |
| Pretax Income | -14.53M |
| Net Income | -14.53M |
| EBITDA | -14.16M |
| EBIT | -14.53M |
| Earnings Per Share (EPS) | -$0.53 |
Balance Sheet
The company has $105.03 million in cash and $225,000 in debt, giving a net cash position of $104.81 million or $3.78 per share.
| Cash & Cash Equivalents | 105.03M |
| Total Debt | 225,000 |
| Net Cash | 104.81M |
| Net Cash Per Share | $3.78 |
| Equity / Book Value | 106.38M |
| Book Value Per Share | 3.84 |
| Working Capital | 106.27M |
Cash Flow
| Operating Cash Flow | -7.24M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.24M |
| FCF Per Share | -$0.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELYM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.33% |
| Shareholder Yield | -4.33% |
| Earnings Yield | -6.36% |
| FCF Yield | -3.17% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |